<DOC>
	<DOCNO>NCT02170649</DOCNO>
	<brief_summary>The purpose study investigate effect food pharmacokinetics single 800 mg oral dose BIA 2-093 healthy volunteer .</brief_summary>
	<brief_title>The Tolerability Effect Food Pharmacokinetics Single 800 mg Oral Dose BIA 2-093</brief_title>
	<detailed_description>Single centre , open label , randomize , two-way crossover study 12 healthy male volunteer . The study consist 2 period separate washout period 14 day . On study period volunteer receive single 800 mg oral dose BIA 2-093 follow either standard high fat content breakfast 10 hour fast .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Subjects eligible entry study fulfil follow inclusion criterion : Male subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 28 kg/m2 , inclusive . Subjects healthy determine pre study medical history , physical examination , neurological examination , EEG , 12lead ECG . Subjects clinical laboratory test clinically acceptable investigator . Subjects negative HBsAg , antiHCV Ab HIV1 HIV2 Ab test screen . Subjects negative alcohol drug abuse screen admission . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 21 unit alcohol week . Subjects significant infection know inflammatory process screen and/or admission . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects acute infection influenza time screen and/or admission . Subjects use prescription drug within four week first dose . Subjects use overthecounter medication exclude oral routine vitamin include mega dose vitamin therapy within one week first dose . Subjects use investigational drug and/or participate clinical trial within two month first admission study . Subjects previously receive BIA 2093 . Subjects donate and/or receive blood blood product within previous two month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>BIA 2-093</keyword>
	<keyword>Eslicarbazepine acetate</keyword>
</DOC>